Soft LXR Agonists for Idiopathic Pulmonary Fibrosis
软 LXR 激动剂治疗特发性肺纤维化
基本信息
- 批准号:10079758
- 负责人:
- 金额:$ 30.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-20 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAgonistApplications GrantsAtherosclerosisBinding ProteinsBiochemicalBiological AssayBleomycinBlood CirculationCardiovascular systemCellular StressCessation of lifeChemicalsChronicCicatrixClinicalDataDevelopmentDiagnosisDiseaseDrug CompoundingDrug usageEnvironmentEnzymesExhibitsExposure toFDA approvedFatty LiverFormulationFoxesFundingGoalsGrantHistologicHumanIn VitroIndividualInhalationInjectionsLXRalpha proteinLaboratoriesLeadLipidsLiverLiver MicrosomesLiver X ReceptorLungLung diseasesMetabolicMindModelingMusOralPathologyPatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacotherapyPhasePirfenidonePlasmaPlasma ProteinsProgram DevelopmentPropertyProteinsPulmonary FibrosisRadiationReceptor ActivationReporterRespiratory FailureRiskRodentSafetyScientistSeriesSerumSeveritiesSilicon DioxideSiteSmall Business Innovation Research GrantSmall Business Technology Transfer ResearchSolubilityStructureStructure of parenchyma of lungTestingTherapeuticTissuesTranscriptUniversitiesValidationWorkabsorptionanalogbaseclinical developmentcommercializationdesigndrug candidatedrug developmentdrug discoveryexhaustexperiencegene synthesisidiopathic pulmonary fibrosisin vitro Assayin vitro activityin vivoinnovationmeetingsmembermortalitymouse modelnovel therapeuticspre-clinicalreceptorregenerativescale upside effectsuccesstherapeutic target
项目摘要
Idiopathic pulmonary fibrosis (IPF) is a highly aggressive lung disease that develops almost exclusively in older
individuals and has limited treatment options. An emerging paradigm in the field is that IPF results from chronic
repetitive insults that exhaust the lung’s regenerative capacity, causing progressive tissue remodeling that leads
to respiratory failure and death in the vast majority of patients. In recent work, we and others have uncovered
that lung tissues from IPF patients, old mice and mice with experimentally-induced pulmonary fibrosis undergo
a host of metabolic changes, including a marked suppression of lipid synthesis. With this understanding in mind,
we recently explored whether restoring lipid synthesis can reduce the severity of pulmonary fibrosis in
experimentally-induced mouse models. To test this, we delivered by systemic injection a potent Liver-X Receptor
(LXR) agonist (T0901317) to mice. Importantly, we found that T0901317 not only significantly augmented lipid
synthesis in the lung but also markedly reduced pathology changes, including decreasing the expression of
cellular stress markers and decreasing biochemical and histological evidence of lung fibrosis. Importantly, the
rationale for this therapeutic approach is based on the firm understanding that LXR activation induces a host of
different lipid synthesis genes and is a well-validated therapeutic target in the drug discovery field. That said,
existing LXR agonists are highly stable in the circulation, contributing to numerous long-term side effects such
as fatty liver and atherosclerosis. Therefore, in our Phase I SBIR we worked to develop an innovative "soft drug"
approach to targeting LXR activation. This approach utilizes medicinal chemistry to synthesize agonists that work
robustly in the lung but become rapidly degraded to inactive compounds upon entry into the circulation. Notably,
our work has led to the development of two structurally diverse series of compounds that possess LXR agonist
activity and exhibit unstable properties in mouse liver microsomes and plasma. In this Phase I STTR proposal,
we seek to further optimize our two series of LXR agonists in order to find preclinical candidates that are optimally
suited for intrapulmonary delivery. To achieve this goal, our proposal is divided into three Specific Aims. In Aim
1 we will design and synthesize specific hypothesis-directed additional soft LXR agonists. In Aim 2, we will
evaluate each of our compounds to confirm that they undergo rapid metabolic clearance (t1/2 < 10 mins) upon
absorption into the circulation using mouse and human plasma and liver microsomes to mimic the in vivo
environment. Finally, in Aim 3, 5-7 of our best compounds will be evaluated in vivo for their ability to induce lipid
synthesis and ameliorate pulmonary fibrosis in acute and chronic (old mice) bleomycin mouse models, and
assess off-target effects of our compounds on other tissues. At the end of this Phase I STTR proposal, we
expect to be poised to initiate a full-fledged drug discovery and development program (Phase II STTR) that will
enable us develop inhalation formulations that ultimately lead to preclinical drug candidates with suitable
efficacy and safety properties to advance directly to IND enabling studies, clinical development and
commercialization.
特发性肺纤维化(IPF)是一种高度侵略性的肺部疾病,几乎完全在较旧的情况下发展
个人,治疗方案有限。该领域的新兴范式是IPF由慢性产生
重复的侮辱会耗尽肺部再生能力,导致进行性组织重塑导致
绝大多数患者的呼吸衰竭和死亡。在最近的工作中,我们和其他人发现了
IPF患者,老鼠和具有实验诱导的肺纤维化的小鼠的肺组织经历
许多代谢变化,包括对脂质合成的明显抑制。考虑到这种理解,
我们最近探讨了恢复脂质合成是否可以减少肺纤维化的严重程度
实验引起的小鼠模型。为了测试这一点,我们通过全身注入潜在的liver-X受体传递
(LXR)激动剂(T0901317)到小鼠。重要的是,我们发现T0901317不仅显着增强了脂质
肺中的合成,但也显着降低了病理变化,包括降低
细胞应力标记并减少肺纤维化的生化和组织学证据。重要的是,
这种治疗方法的基本原理是基于坚定的理解,即LXR激活诱导了许多
不同的脂质合成基因,是药物发现领域中有验证的治疗靶标。就是说,
现有的LXR激动剂在循环中非常稳定,导致了许多长期副作用
作为脂肪肝和动脉粥样硬化。因此,在我们的第一阶段,我们致力于开发创新的“软药”
靶向LXR激活的方法。这种方法利用医学化学来合成起作用的激动剂
进入循环时,在肺部稳健,但在进入循环时会迅速降解为无活性化合物。尤其,
我们的工作导致了具有LXR激动剂的两个结构上多样化的化合物的发展
小鼠肝微粒体和血浆中的活性和表现出不稳定的特性。在这个阶段,我的sttr提案,
我们寻求进一步优化我们的两个系列LXR激动剂,以便找到最佳的临床前候选者
适合肺内输送。为了实现这一目标,我们的建议分为三个具体目标。目标
1我们将设计和合成特定假设指导的其他软LXR激动剂。在AIM 2中,我们将
评估我们的每种化合物,以确认它们会在
使用小鼠和人血浆和肝微粒体抽象进入循环系统,以模仿体内
环境。最后,在AIM 3,我们最好的化合物的5-7中,将在体内评估其诱导脂质的能力
急性和慢性(旧小鼠)博来霉素小鼠模型中的合成和改善肺纤维化,以及
评估我们化合物对其他组织的脱靶作用。在此阶段我的sttr提案结束时,我们
期望被中毒启动成熟的药物发现和开发计划(II阶段STTR),该计划将
使美国开发吸入配方最终导致临床前药物候选者
有效性和安全性直接提高到IND促进研究,临床发展和
商业化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ross S Summer其他文献
Ross S Summer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ross S Summer', 18)}}的其他基金
Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
靶向乳胶蛋白信号传导治疗炎症性肺损伤中的内皮屏障功能障碍
- 批准号:
10661225 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
靶向乳胶蛋白信号传导治疗炎症性肺损伤中的内皮屏障功能障碍
- 批准号:
10676165 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
靶向乳胶蛋白信号传导治疗炎症性肺损伤中的内皮屏障功能障碍
- 批准号:
10677334 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
靶向乳胶蛋白信号传导治疗炎症性肺损伤中的内皮屏障功能障碍
- 批准号:
10457247 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
Metabolic control of DNA repair in pulmonary fibrosis
肺纤维化中 DNA 修复的代谢控制
- 批准号:
9238175 - 财政年份:2017
- 资助金额:
$ 30.65万 - 项目类别:
Metabolic control of DNA repair in pulmonary fibrosis
肺纤维化中 DNA 修复的代谢控制
- 批准号:
9405624 - 财政年份:2017
- 资助金额:
$ 30.65万 - 项目类别:
Adiponectin inhibits activation and injury of lung endothelium
脂联素抑制肺内皮细胞的活化和损伤
- 批准号:
8303403 - 财政年份:2011
- 资助金额:
$ 30.65万 - 项目类别:
Adiponectin inhibits activation and injury of lung endothelium
脂联素抑制肺内皮细胞的活化和损伤
- 批准号:
8186653 - 财政年份:2011
- 资助金额:
$ 30.65万 - 项目类别:
Adiponectin inhibits activation and injury of lung endothelium
脂联素抑制肺内皮细胞的活化和损伤
- 批准号:
8687725 - 财政年份:2011
- 资助金额:
$ 30.65万 - 项目类别:
Adiponectin inhibits activation and injury of lung endothelium
脂联素抑制肺内皮细胞的活化和损伤
- 批准号:
8852162 - 财政年份:2011
- 资助金额:
$ 30.65万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:82101697
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Prevention of intracellular infection in diabetic wounds by commensal Staphylococcus epidermidis
共生表皮葡萄球菌预防糖尿病伤口细胞内感染
- 批准号:
10679628 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Stabilizing the tripartite synaptic complex following TBI
TBI 后稳定三方突触复合体
- 批准号:
10844877 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Spine Surgery (MIRHIQL)
为脊柱手术中长期使用阿片类药物的患者整合定制的术后阿片类药物逐渐减量和疼痛管理支持 (MIRHIQL)
- 批准号:
10722943 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Assay to Improve Translation in Analgesic Drug Development
改善镇痛药物开发转化的新方法
- 批准号:
10726834 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Alcohol-induced epigenetic reprogramming of PPAR-α affects allopregnanolone biosynthesis
酒精诱导的 PPAR-α 表观遗传重编程影响异孕酮生物合成
- 批准号:
10658534 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别: